Related references
Note: Only part of the references are listed.Driving gene-engineered T cell immunotherapy of cancer
Laura A. Johnson et al.
CELL RESEARCH (2017)
Human Monocytes in the Presence of Interferons Alpha2a and Gamma Are Potent Killers of Serous Ovarian Cancer Cell Lines in Combination with Paclitaxel and Carboplatin
Chase L. Johnson et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
The biology of innate lymphoid cells
David Artis et al.
NATURE (2015)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
Macrophage heterogeneity in tissues: phenotypic diversity and functions
Siamon Gordon et al.
IMMUNOLOGICAL REVIEWS (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Immunomodulatory Effects of Interferons in Malignancies
Joseph Bekisz et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer
Chunyan Lan et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2013)
Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors
Hideyuki Nakashima et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Monocytes control natural killer cell differentiation to effector phenotypes
Katrina Soderquest et al.
BLOOD (2011)
Near Eradication of Clinically Relevant Concentrations of Human Tumor Cells by Interferon-Activated Monocytes In Vitro
Samuel Baron et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical model:: Interferons activate human monocytes to an eradicative tumor cell level in vitro
Samuel Baron et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2007)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Monocyte and macrophage heterogeneity
S Gordon et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
GJS Rustin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Clinical disease course during the last year in ovarian cancer
VE von Gruenigen et al.
GYNECOLOGIC ONCOLOGY (2003)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]
I Vergote et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
